Millie Das, MD, highlights early efficacy signals with PARP inhibitors in patients with small cell lung cancer, how overall survival data from the phase 3 ADAURA trial confirm the efficacy of adjuvant osimertinib in patients with non–small cell lung cancer, and which patients may benefit most from immunotherapy as monotherapy or in combination with other agents.
Experts from various institutions were interviewed by OncLive® at the 24th Annual International Lung Cancer Congress® about the ongoing platinum chemotherapy shortage in the United States.
Millie Das, MD, discusses the current landscape of new and emerging ADCs under investigation in small-cell lung cancer and highlights the phase 2 SWOG S1929 study.